Studie - HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H2 2012

HIV-Associated Lipodystrophy Syndrome — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H2 2012', provides an overview of the HIV-Associated Lipodystrophy Syndrome therapeutic pipeline. This report provides information on the therapeutic development for HIV-Associated Lipodystrophy Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-Associated Lipodystrophy Syndrome. 'HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for HIV-Associated Lipodystrophy Syndrome.
- A review of the HIV-Associated Lipodystrophy Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the HIV-Associated Lipodystrophy Syndrome pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for HIV-Associated Lipodystrophy Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding HIV-Associated Lipodystrophy Syndrome pipeline depth and focus of HIV-Associated Lipodystrophy Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

HIV-Associated Lipodystrophy Syndrome Overview 6

Therapeutics Development 7

An Overview of Pipeline Products for HIV-Associated Lipodystrophy Syndrome 7

HIV-Associated Lipodystrophy Syndrome Therapeutics under Development by Companies 9

HIV-Associated Lipodystrophy Syndrome Therapeutics under Investigation by Universities/Institutes 10

Late Stage Products 11

Comparative Analysis 11

Mid Clinical Stage Products 12

Comparative Analysis 12

Early Clinical Stage Products 13

Comparative Analysis 13

HIV-Associated Lipodystrophy Syndrome Therapeutics — Products under Development by Companies 14

HIV-Associated Lipodystrophy Syndrome Therapeutics — Products under Investigation by Universities/Institutes 15

Companies Involved in HIV-Associated Lipodystrophy Syndrome Therapeutics Development 16

Theratechnologies Inc. 16

HIV-Associated Lipodystrophy Syndrome — Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Combination Products 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Drug Profiles 23

Egrifta - Drug Profile 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Serostim - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Avandia - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Recombinant Human Growth Hormone + Avandia - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Leptin - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Recombinant IGF-I - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

HIV-Associated Lipodystrophy Syndrome Therapeutics — Drug Profile Updates 32

HIV-Associated Lipodystrophy Syndrome Therapeutics — Discontinued Products 37

HIV-Associated Lipodystrophy Syndrome Therapeutics - Dormant Products 38

HIV-Associated Lipodystrophy Syndrome — Product Development Milestones 39

Featured News & Press Releases 39

Jun 22, 2012: Theratechnologies Provides Regulatory Update On Tesamorelin 39

Jun 04, 2012: Theratechnologies Announces Submission Of Marketing Authorization Application For Tesamorelin In Colombia And Venezuela 39

Dec 07, 2011: Theratechnologies To Discontinue COPD Clinical Program And Accelerate Path To Profitability 40

Oct 19, 2011: Theratechnologies Announces Application For Registration Of Tesamorelin In Mexico 41

Aug 31, 2011: Theratechnologies Announces Marketing Authorization Application For Tesamorelin In Brazil 41

Jul 05, 2011: Theratechnologies Announces Filing Of Application For Registration Of Tesamorelin In Israel By Sanofi 41

Jun 06, 2011: Theratechnologies Announces Filing Of European Marketing Authorization Application For Tesamorelin 42

Jun 24, 2010: Theratechnologies Announces Publication Of Combined Tesamorelin Phase III Results In JCEM 43

May 27, 2010: Theratechnologies Announces Positive Vote By FDA Advisory Committee For Tesamorelin 43

Mar 22, 2010: FDA Confirms Date For Advisory Committee Review Of Theratechnologies' Tesamorelin New Drug Application 44

Appendix 45

Methodology 45

Coverage 45

Secondary Research 45

Primary Research 45

Expert Panel Validation 45

Contact Us 46

Disclaimer 46





List of Tables

Number of Products Under Development for HIV-Associated Lipodystrophy Syndrome, H2 2012 7

Products under Development for HIV-Associated Lipodystrophy Syndrome — Comparative Analysis, H2 2012 8

Number of Products under Development by Companies, H2 2012 9

Number of Products under Investigation by Universities/Institutes, H2 2012 10

Comparative Analysis by Late Stage Development, H2 2012 11

Comparative Analysis by Mid Clinical Stage Development, H2 2012 12

Comparative Analysis by Early Clinical Stage Development, H2 2012 13

Products under Development by Companies, H2 2012 14

Products under Investigation by Universities/Institutes, H2 2012 15

Theratechnologies Inc., H2 2012 16

Assessment by Monotherapy Products, H2 2012 17

Assessment by Combination Products, H2 2012 18

Assessment by Stage and Route of Administration, H2 2012 20

Assessment by Stage and Molecule Type, H2 2012 22

HIV-Associated Lipodystrophy Syndrome Therapeutics — Drug Profile Updates 32

HIV-Associated Lipodystrophy Syndrome Therapeutics — Discontinued Products 37

HIV-Associated Lipodystrophy Syndrome Therapeutics — Dormant Products 38





List of Figures

Number of Products under Development for HIV-Associated Lipodystrophy Syndrome, H2 2012 7

Products under Development for HIV-Associated Lipodystrophy Syndrome — Comparative Analysis, H2 2012 8

Products under Development by Companies, H2 2012 9

Products under Investigation by Universities/Institutes, H2 2012 10

Late Stage Products, H2 2012 11

Mid Clinical Stage Products, H2 2012 12

Early Clinical Stage Products, H2 2012 13

Assessment by Monotherapy Products, H2 2012 17

Assessment by Combination Products, H2 2012 18

Assessment by Route of Administration, H2 2012 19

Assessment by Stage and Route of Administration, H2 2012 20

Assessment by Molecule Type, H2 2012 21

Assessment by Stage and Molecule Type, H2 2012 22

• Emergency Contraception in Canada
• Emergency Contraception in Denmark
• Emergency Contraception in Norway
• Emergency Contraception in Azerbaijan
• Emergency Contraception in China
• Emergency Contraception in Finland
• Emergency Contraception in Kazakhstan
• Emergency Contraception in Latvia
• Emergency Contraception in Lithuania
• Emergency Contraception in Sweden
• Emergency Contraception in the US
• Emergency Contraception in Australia
• Emergency Contraception in Uruguay
• Emergency Contraception in Kenya
• Emergency Contraception in Portugal
• Emergency Contraception in the Netherlands
• Emergency Contraception in Austria
• Emergency Contraception in Nigeria
• Emergency Contraception in Serbia
• Emergency Contraception in Belgium